Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust
Eli Lilly’s high hopes for its IL-23 anti-inflammatory drug mirikizumab were borne out by a successful round of Phase III data demonstrating its superiority to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
